A new study conducted in Finland has discovered a new medication that could offer a new treatment option for patients with advanced melanoma, the most dangerous form of skin cancer. The medication, relatlimab, has been found to affect the immune system in a different way compared to other therapies that activate the immune system.
Typically, therapies have been designed to activate T cells to attack cancer cells.
A study at the University of Jyväskylä found that men are biologically older than women. The observed sex difference is partially explained by men's more frequent smoking and larger body size.
E-Mail
IMAGE: SORLA removal sensitizes metastatic breast cancer cells to HER2 targeting therapy. Aggressive metastatic breast cancer cells growing in the brains of fish embryos. The tumors are resistant to anti-HER2 therapy. view more
Credit: Ilkka Paatero from Turku Bioscience
SORLA is a protein trafficking receptor that has been mainly studied in neurons, but it also plays a role in cancer cells. Professor Johanna Ivaska s research group at Turku Bioscience observed that SORLA functionally contributes to the most reported therapy-resistant mechanism by which the cell-surface receptor HER3 counteracts HER2 targeting therapy in HER2-positive cancers. Removing SORLA from cancer cells sensitized anti-HER2 resistant breast cancer brain metastasis to targeted therapy.